secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001193125-26-157940
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics appoints Cheryl Blanchard to Board; Rossi resigns
--------------------------------------------------------------------

- Cheryl Blanchard elected as Class III director effective April 15, 2026; term expires at 2027 annual meeting.
- Blanchard appointed chair of Compensation Committee and member of Audit Committee.
- Blanchard receives $40k annual cash retainer, $12k for Comp chair, $7.5k for Audit; initial option for 10k shares vesting over 3 years.
- Christina Rossi resigned from Board on April 15, 2026; resignation not due to any disagreement with company.
- Board adopted amended Non-Employee Director Compensation Policy effective April 15, 2026 (Exhibit 10.1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526157940/0001193125-26-157940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312526157940/xlo-20260416.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-157940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer